Articles tagged with: Vidaza

News»

[ by | Mar 19, 2014 5:42 pm | Comments Off ]
Pre-Transplant Vidaza May Improve Stem Cell Transplant Outcomes In Higher-Risk MDS Patients

Results of a small pro­spec­tive study conducted at the Lee Moffitt Cancer Center suggest that pre-trans­plant treatment with Vidaza may improve the outcomes of donor stem cell trans­planta­tion in higher-risk myelo­dys­plas­tic syndromes patients.

Patients in the study received a median of three cycles of Vidaza (aza­citi­dine) before proceeding to high-dose chemotherapy followed by a donor stem cell trans­plant.  The Vidaza was administered to each patient while a stem cell donor was sought on their behalf.

About half of the patients had previously been treated with Vidaza or Dacogen (decitabine), a …

Read the full story »

News»

[ by and | Jan 30, 2014 5:22 pm | Comments Off ]
Spanish Analysis Provides Further Insights Into Effectiveness Of Vidaza For Older MDS Patients

Results from a recent retrospective analysis conducted in Spain show that treat­ment with Vidaza is feasible, and can have important benefits, in mye­lo­dys­plas­tic syndromes patients at least 75 years of age.

Forty percent of the patients in the study – who were all 75 years of age or older – achieved trans­fusion in­de­pen­dence.  In addition, achieving trans­fusion independence was associated with more than just an improve­ment in quality of life.  Patients in the study who achieved transfusion in­de­pendence had a median overall survival twice as long as those who did …

Read the full story »

News»

[ by | Jan 22, 2014 12:56 pm | Comments Off ]
Mocetinostat In Combination With Vidaza Shows High Activity In MDS Patients (ASH 2013)

A sub-analysis of results from a recent Phase 1/2 study shows that the inves­ti­ga­tion­al drug mocetinostat in combination with Vidaza is highly active in myelo­dys­plastic syndromes patients.

In particular, the results show that 64 percent of the patients in the study, who had intermediate- and high-risk myelodysplastic syndromes (MDS), responded to treatment, with 50 percent achieving a complete response.

In addition, 33 percent of patients achieved transfusion independence.

Dr. Guillermo Garcia-Manero from the M.D. Anderson Cancer Center in Houston presented the results dur­ing a poster session at the American Society of Hematology …

Read the full story »

News»

[ by | Dec 20, 2013 2:28 pm | Comments Off ]
Zolinza Plus Vidaza Yields High Response Rate And Extended Survival In Higher-Risk MDS (ASH 2013)

Results of a recent Phase 2 study indicate that Zolinza in com­bi­na­tion with Vidaza is effective and safe in intermediate- and high-risk myelodysplastic syn­dromes patients.

Overall, 75 percent of patients in the trial responded to the two-drug reg­i­men, and 35 percent achieved a complete response.  According to the study’s lead in­ves­ti­ga­tor – Dr. Lewis Silverman from the Tisch Cancer Institute in New York City – these response rates are superior to those seen for treatment with Vidaza (azacitidine) alone.  Single-agent Vidaza had an overall response rate of 49 percent in a key trial, …

Read the full story »

News»

[ by | Dec 11, 2013 5:04 pm | Comments Off ]
ASH 2013 Myelodysplastic Syndromes Update – Day Three & Day Four

Yesterday was the final day of this year’s American Society of Hematology (ASH) meeting, which took place in New Orleans.

Sessions throughout the day on Monday and yesterday featured a wide range of interesting presentations about myelodysplastic syndromes (MDS).

For example, initial results of a Phase 2 study of Zolinza (vorinostat) in combination with Vidaza (azacitidine) show that three-quarters of patients responded to the treatment combination and the median overall survival was 27.6 months, which is greater than what has been observed with Vidaza alone.

Another study showed that the …

Read the full story »